Revolution Medicines, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Revolution Medicines is a clinical-stage biopharmaceutical company developing targeted therapies for RAS-addicted cancers, including drug candidates aimed at inhibiting mutant forms of the RAS protein family implicated in tumors such as pancreatic, lung, and colorectal cancer.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| ANDERSON ELIZABETH MInsider | Sell | $960K | 4,985at $192.54 | Sep 22, 2026 |
| ANDERSON ELIZABETH MInsider | Sell | $512K | 2,648at $193.44 | Sep 22, 2026 |
| ANDERSON ELIZABETH MInsider | Sell | $292K | 1,500at $194.59 | Sep 22, 2026 |
| ANDERSON ELIZABETH MInsider | Sell | $175K | 910at $191.85 | Sep 22, 2026 |
| ANDERSON ELIZABETH MInsider | Sell | $20K | 100at $195.15 | Sep 22, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable RVMD activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.